Protara Completes Enrollment in Phase 2b Portion of IV Choline Chloride Trial
Protara Therapeutics completed enrollment of 24 patients in the Phase 2b dose-confirmation portion of its registrational THRIVE-3 trial of IV Choline Chloride. The treatment targets choline deficiency in patients with intestinal failure who depend on parenteral support. Interim Phase 2b results are expected in the four